One of the primary challenges in managing CINV is the interindividual variability in response to both chemotherapy and antiemetic treatments. Genetic differences in metabolism and receptor sensitivity can influence a patient's susceptibility to CINV and response to antiemetics. Additionally, the development of new chemotherapy agents with unique toxicological profiles necessitates ongoing research into effective management strategies.
